Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.6K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Cancer Vaccines01:30

Cancer Vaccines

867
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
867
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

319
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
319
Clinical Trials01:16

Clinical Trials

10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: Near-infrared fatty acid molecular probe for image-guided surgery of glioblastoma.

Npj imaging·2026
Same author

Repurposing licensed viral vaccines as anti-cancer therapeutics: Turning cold tumors hot.

Human vaccines & immunotherapeutics·2026
Same author

Increased or decreased numbers of CpG dinucleotide motifs in the genome of influenza A virus do not affect <i>in vitro</i> virus phenotype.

Journal of virology·2026
Same author

Boosting CAR T cell functionality with oncolytic viruses for the treatment of pediatric diffuse midline gliomas.

Molecular therapy. Oncology·2026
Same author

Selector adeno-associated viral vectors facilitate on-target precise genome editing and purge off-target chromosomal insertions.

Trends in biotechnology·2026
Same author

Improved oncolytic and immunostimulatory activity of the spontaneous <i>jin-3</i> reovirus mutant in preclinical bladder cancer models.

Molecular therapy. Oncology·2026

Related Experiment Video

Updated: Dec 18, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.0K

Developing oncolytic viruses for clinical use: A consortium approach.

Vera Kemp1, Martine L M Lamfers2, Gabri van der Pluijm3

  • 1Department of Cell and Chemical Biology, Leiden University Medical Center, 2333 ZC, Leiden, Netherlands.

Cytokine & Growth Factor Reviews
|June 20, 2020
PubMed
Summary

Oncolytic viruses offer a promising cancer treatment by killing tumor cells and stimulating anti-tumor immunity. This review outlines their development and introduces a Dutch academic consortium focused on creating and testing novel oncolytic viruses for various cancers.

Keywords:
Cancer therapyImmunotherapyOncolytic virusTranslational research

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.4K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.0K

Related Experiment Videos

Last Updated: Dec 18, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.0K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.4K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.0K

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Oncolytic viruses represent a promising cancer therapy, selectively replicating within and destroying tumor cells.
  • Viral infection triggers both virus-specific and tumor-specific immune responses, enhancing anti-cancer effects.
  • Despite academic initiation, industry largely leads late-stage development and clinical trials, limiting comparative studies.

Purpose of the Study:

  • To review the essential steps and considerations in the development and characterization of oncolytic viruses.
  • To introduce a multidisciplinary academic consortium dedicated to oncolytic virus development.
  • To outline the consortium's ambition to develop and evaluate a series of oncolytic viruses in diverse cancer types.

Main Methods:

  • Literature review of oncolytic virus development and characterization.
  • Description of a multidisciplinary academic consortium involving multiple Dutch universities.
  • Outline of plans for developing and evaluating oncolytic viruses in preclinical and clinical settings.

Main Results:

  • Oncolytic viruses possess a dual mechanism of action: direct tumor cell lysis and immune system activation.
  • A significant gap exists in comparative preclinical and clinical studies evaluating different oncolytic viruses.
  • A collaborative academic consortium has been established to address these development and evaluation challenges.

Conclusions:

  • Oncolytic virus therapy holds significant potential for cancer treatment.
  • Standardized development and comparative evaluation are crucial for advancing oncolytic virus therapies.
  • The described academic consortium aims to contribute to the development of effective oncolytic virus treatments for various cancers.